In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease

Nuclear Medicine and Biology

Volumn 33, Issue 3, 2006, Pages 305-309

  Schmaljohann, Jörn ^a   Gündisch, Daniela ^a   Minnerop, Martina ^a   Bucerius, Jan ^a   Joe, Alexius ^a   Reinhardt, Michael ^a   Guhlke, Stefan ^a   Biersack, Hans Jürgen ^a   Wüllner, Ullrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

2 18F A85380; Fluorine 18; Nicotinic acetylcholine receptor; Parkinson's disease; PET

Indexed keywords

2 FLUORO 3 (2 AZETIDINYLMETHOXY)PYRIDINE F 18; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; NICOTINIC ALPHA2 BETA4 RECEPTOR; NICOTINIC RECEPTOR; TRACER; UNCLASSIFIED DRUG;

AGED; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN CORTEX; BRAIN DAMAGE; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTERNEURON; MALE; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN LOCALIZATION; PUTAMEN; RAT; SENSORY NERVE CELL; SUBSTANTIA NIGRA; THALAMUS;

ANIMALS; AUTORADIOGRAPHY; AZETIDINES; BRAIN; FLUORINE RADIOISOTOPES; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; TISSUE DISTRIBUTION;

EID: 33646029408     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2005.12.012     Document Type: Article

References (25)

1. Whitehouse P.J., Martino A.M., Antuono P.G., Lowenstein P.R., Coyle J.T., Price D.L., et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 371 (1986) 146-151
2. Martin-Ruiz C.M., Piggott M., Gotti C., Lindstrom J., Mendelow A.D., Siddique M.S., et al. Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease. Neuropharmacology 39 (2000) 2830-2839
3. 125I]-A-85380. Neuropsychopharmacology 29 (2004) 108-116
4. Court J.A., Piggott M.A., Lloyd S., Cookson N., Ballard C.G., McKeith I.G., et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 98 (2000) 79-87
5. Quik M., Bordia T., Forno L., and McIntosh J.M. Loss of a-conotoxin MII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum. J Neurochem 88 (2004) 668-679
6. 11C]cotinine. Preparation, metabolites studies and in vivo distribution in human brain using PET. Nucl Med Biol 19 (1992) 871-880
7. 11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology 115 (1994) 31-36
8. 18F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane. Journal of Labelled Compounds and Radiopharmaceuticals 38 (1996) 355-365
9. Koren A.O., Horti A.G., Mukhin A.G., Gündisch D., Kimes A.S., Dannals R.F., et al. 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J Med Chem 41 (1998) 3690-3698
10. Mukhin A.G., Gündisch D., Horti A.G., Koren A.O., Tamagnan G., Kimes A.S., et al. 5-Iodo-A-85380, an a4b2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 57 (2000) 642-649
11. 18F]F-A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J 17 (2003) 1331-1343
12. 18F-fluoro-A-85380 in healthy volunteers. J Nucl Med 44 (2003) 596-601
13. 18F-A-85380. Vogt-Brodmann-Symposium, Jülich (2004) (unpublished observation)
14. 18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. Appl Radiat Isot 61 (2004) 1235-1240
15. Wüllner U., Young A.B., Penney J.B., and Beal M.F. 3-Nitropropionic acid toxicity in the striatum. J Neurochem 63 (1994) 1772-1781
16. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1998), Academic Press, San Diego
17. de Groote C., Wüllner U., Löschmann P.A., Luiten P.G., and Klockgether T. Functional characterization and expression of thalamic GABA(B) receptors in a rodent model of Parkinson's disease. Neuropharmacology 38 (1999) 1683-1689
18. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-211
19. 3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J Pharmacol Exp Ther 275 (1995) 1030-1034
20. Lukas R.J., Changeux J.P., Le Novere N., Albuquerque E.X., Balfour D.J., Berg D.K., et al. International Union of Pharmacology. XX. Current Status of the Nomenclature for Nicotinic Acetylcholine Receptors and their Subunits. Pharmacol Rev 51 (1999) 397-401
21. Holladay M.W., Dart M.J., and Lynch J.K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 40 (1997) 4169-4194
22. Quik M., Sum J.D., Whiteaker P., McCallum S.E., Marks M.J., Musachio J.L., et al. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol 63 (2003) 1169-1179
23. Kulak J.M., Muschio J.L., McIntosh J.M., and Quik M. Declines in different 2* nicotinic receptor populations in monkey striatum after nigrostriatal damage. J Pharmacol Exp Ther 303 (2002) 633-639
24. Kulak J.M., Sum J., Musachio J.L., McIntosh J.M., and Quick M. 5-Iodo-A-85380 binds to α-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as α4β2* subtypes. J Neurochem 81 (2002) 403-406
25. 11C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. J Neural Transm. 2005 Jun 15; [Electronic publication ahead of print].